Prostate Cancer Diagnostics Market Size, Share, Growth, and Industry Analysis, By Types (Tumor Biomarker Tests, Imaging, Biopsy, Other) , Applications (Age Below 55, Age 55-75, Age Above 75) and Regional Insights and Forecast to 2034

Prostate Cancer Diagnostics Market Size

The Global Prostate Cancer Diagnostics Market size was USD 15.59 billion in 2024 and is projected to reach USD 16.81 billion in 2025. It is further anticipated to grow significantly and touch USD 30.65 billion by 2034, showcasing a steady compound annual growth rate (CAGR) of 7.8% during the forecast period from 2025 to 2034. This growth is supported by an increasing volume of diagnostic screenings, with over 55% of men above the age of 55 undergoing routine prostate cancer testing. The adoption of non-invasive diagnostic technologies has increased by 42%, while hospital-based diagnostics account for more than 40% of global demand.

The US Prostate Cancer Diagnostics Market remains a global leader, accounting for nearly 36% of the total global share. More than 58% of diagnostic procedures in North America are prostate cancer-related, with over 61% of patients between ages 55–75 receiving regular PSA testing. Genomic diagnostics usage in the US rose by 34%, and hospital investments in cancer diagnostics increased by 28%. Additionally, over 47% of new product launches in this segment originated from US-based companies, highlighting innovation leadership in diagnostics and personalized medicine.

Key Findings

• Market Size: $15.59 billion (2024), $16.81 billion (2025), $30.65 billion (2034); CAGR of 7.8% from 2025 to 2034.
• Growth Drivers: Over 55% PSA testing uptake, 42% increase in non-invasive diagnostics, 34% surge in genomic testing demand, 28% rise in lab automation.
• Trends: 38% of hospitals now use AI-enhanced diagnostics, 31% growth in liquid biopsy tools, 26% rise in home-based screening kits.
• Key Players: Roche, Abbott, Genomic Health, Beckman Coulter, Siemens Healthcare & more.
• Regional Insights: North America holds 42% of the market driven by advanced diagnostics; Europe follows with 28%, Asia-Pacific holds 22%, while the Middle East & Africa accounts for 8% due to growing awareness and healthcare access.
• Challenges: 36% of patients cite diagnostic costs as a barrier, 41% in rural regions lack access to advanced tools, 33% rely on outdated PSA-only methods.
• Industry Impact: 29% diagnostic accuracy improvement with AI, 35% faster patient turnaround, 27% increase in early detection cases due to innovative tools.
• Recent Developments: 31% rise in AI-powered tools, 22% increase in home kits, 26% more clinical partnerships, 18% product launches in non-invasive diagnostics.

The Global Prostate Cancer Diagnostics Market is expanding through technological integration, with AI-based analysis and molecular diagnostics transforming early detection. Innovations are focused on accuracy, speed, and patient comfort. Growth is also driven by rising awareness, increasing male health screening rates, and a strong pipeline of diagnostic devices tailored for different age groups and risk categories.

Prostate Cancer Diagnostics Market Trends

The prostate cancer diagnostics market is undergoing significant transformation, driven by rising awareness and technological advancements. Non-invasive diagnostic techniques now account for over 45% of market share, reflecting the shift toward patient-friendly solutions. Biomarker-based tests have seen a 32% increase in adoption, while imaging techniques such as multiparametric MRI have grown by 28%. Among diagnostics methods, PSA (Prostate-Specific Antigen) testing continues to dominate with a 55% usage rate, though new genomic testing tools are gaining traction with a growth rate of 23%. Hospital laboratories represent over 40% of the diagnostic channel usage, while diagnostics performed in diagnostic labs are rising at a pace of 18% annually due to convenience and accessibility.

Prostate Cancer Diagnostics Market Dynamics

DRIVERS

"Rising prevalence of prostate cancer cases globally"

Prostate cancer represents over 13% of all male cancer diagnoses, and its detection rate has increased by 21% due to regular screening programs. Increased awareness campaigns have contributed to a 26% rise in early-stage diagnoses, leading to growing demand for advanced diagnostic tools.

OPPORTUNITY

"Growth in demand for genomic and biomarker testing"

The demand for biomarker-based diagnostics has grown by 32%, particularly among patients opting for precision medicine. Genomic testing solutions have shown a 29% uptick in clinical adoption. Healthcare providers report a 35% improvement in diagnostic accuracy when incorporating molecular testing in prostate cancer diagnostics.

RESTRAINTS

"Limited access in low-income and rural regions"

Over 38% of rural health centers report limited access to modern diagnostic tools. The availability of advanced prostate cancer diagnostics in underdeveloped areas is below 25%, with nearly 41% of patients in remote locations depending solely on PSA tests due to cost and infrastructure limitations.

CHALLENGE

"High cost of advanced diagnostic procedures"

Advanced diagnostic techniques such as genomic sequencing and mpMRI face affordability challenges, with over 36% of patients citing cost as a deterrent. Private diagnostic centers report that 42% of individuals defer testing due to pricing barriers, affecting timely and accurate cancer detection.

Segmentation Analysis

The global prostate cancer diagnostics market is segmented by type and application, with tumor biomarker tests, imaging, and biopsy technologies leading innovation and adoption. In 2025, the overall market is projected to reach USD 16.81 Billion, with tumor biomarker tests holding the largest share due to high usage in early detection. Biopsy and imaging technologies are rapidly expanding with increasing clinical integration. Between 2025 and 2034, the market is expected to grow at a CAGR of 7.8%, reaching USD 30.65 Billion. Application-wise, diagnostics in hospitals and laboratories dominate due to access to specialized facilities and skilled professionals.

By Type

Tumor Biomarker Tests

Tumor biomarker tests are widely used for early detection and monitoring of prostate cancer, especially PSA-based screening. These tests now contribute to over 38% of all prostate cancer diagnostics globally. Advancements in genomic and proteomic assays have led to a 34% rise in test accuracy and a 29% increase in physician preference for early-stage identification.

Tumor Biomarker Tests held the largest share in the prostate cancer diagnostics market, accounting for USD 6.50 Billion in 2025, representing 38.7% of the total market. This segment is expected to grow at a CAGR of 8.3% from 2025 to 2034, driven by rising awareness, non-invasive nature, and high diagnostic efficiency.

Top 3 Major Dominant Countries in the Tumor Biomarker Tests Segment

• United States led the Tumor Biomarker Tests segment with a market size of USD 2.62 Billion in 2025, holding a 40.3% share and expected to grow at a CAGR of 8.5% due to advanced healthcare infrastructure and regular screening programs.
• Germany held USD 0.92 Billion in 2025 with a 14.1% share and a projected CAGR of 8.1%, driven by early adoption of genomic diagnostics and public health initiatives.
• Japan recorded USD 0.81 Billion in 2025, securing a 12.4% share and forecasted to grow at a CAGR of 8.0%, supported by a high aging population and government-funded diagnostic programs.

Imaging

Imaging diagnostics such as multiparametric MRI and PET scans are critical for staging and guiding prostate cancer treatment. Imaging holds approximately 26% of the global market, with a 31% increase in usage among hospitals and cancer centers. Technological integration of AI in imaging has boosted diagnostic confidence by 27%.

Imaging accounted for USD 4.37 Billion in 2025, representing a 26% market share. It is expected to grow at a CAGR of 7.5% from 2025 to 2034, fueled by improvements in image resolution, accessibility, and clinician demand for high-accuracy staging tools.

Top 3 Major Dominant Countries in the Imaging Segment

• United States led the Imaging segment with a market size of USD 1.88 Billion in 2025, holding a 43.0% share and expected to grow at a CAGR of 7.6% due to widespread MRI integration in clinical protocols.
• United Kingdom held USD 0.61 Billion in 2025, capturing 14.0% of the market with a CAGR of 7.3%, thanks to the expansion of radiology services and cancer awareness campaigns.
• Canada secured USD 0.53 Billion in 2025, holding an 12.1% share, expected to grow at a CAGR of 7.2%, supported by strong reimbursement frameworks and government investments in oncology diagnostics.

Biopsy

Biopsy remains the gold standard for confirming prostate cancer, with over 30% global utilization. Innovations in image-guided and fusion biopsy techniques have improved accuracy by 24%. Transperineal biopsy procedures now account for 18% of all prostate biopsies due to lower infection risks.

Biopsy is projected to reach USD 4.88 Billion in 2025, capturing 29% of the prostate cancer diagnostics market. This segment is expected to expand at a CAGR of 7.6% from 2025 to 2034, driven by rising precision diagnostics, clinician preference, and enhanced safety techniques.

Top 3 Major Dominant Countries in the Biopsy Segment

• United States led the Biopsy segment with a market size of USD 2.14 Billion in 2025, holding a 43.8% share, growing at a CAGR of 7.8% due to adoption of image-guided biopsies and robotics.
• France held USD 0.63 Billion in 2025, with a 12.9% share and a CAGR of 7.5%, supported by national screening efforts and clinical upgrades in urology departments.
• Italy secured USD 0.52 Billion in 2025, accounting for a 10.7% share, expected to grow at a CAGR of 7.3% due to early detection policies and public health investments.

Other

The "Other" segment includes digital rectal exams (DRE), urine-based tests, and emerging blood-based technologies. These methods contribute to about 6.3% of the market. Urine-based tests have seen a 22% increase in adoption due to non-invasiveness, while AI-based screening platforms have gained 17% user traction globally.

The Other segment is estimated to reach USD 1.06 Billion in 2025, accounting for 6.3% of the market share. It is expected to grow at a CAGR of 6.5% from 2025 to 2034, driven by innovation in liquid biopsy, home test kits, and AI diagnostics.

Top 3 Major Dominant Countries in the Other Segment

• United States led the Other segment with USD 0.43 Billion in 2025, holding a 40.5% share and growing at a CAGR of 6.8% due to rapid tech adoption and self-testing trends.
• South Korea held USD 0.22 Billion in 2025 with a 20.7% share and a CAGR of 6.3%, backed by digital health platforms and AI integration.
• Australia secured USD 0.18 Billion in 2025, with a 16.9% share and projected CAGR of 6.1%, due to government-driven telehealth programs and preventive screening tools.

By Application

Age Below 55

Although prostate cancer is more prevalent in older age groups, diagnosis among men under 55 is growing steadily. This segment represents about 18% of total cases and has shown a 24% increase in early screening, largely attributed to rising health awareness and genetic testing. Approximately 21% of men below 55 with a family history are now undergoing regular biomarker testing.

The Age Below 55 segment accounted for USD 3.03 Billion in 2025, representing 18% of the global market. It is expected to grow at a CAGR of 7.2% from 2025 to 2034, driven by proactive health behavior, family history awareness, and genetic screening demand.

Top 3 Major Dominant Countries in the Age Below 55 Segment

• United States led the Age Below 55 segment with a market size of USD 1.21 Billion in 2025, holding a 39.9% share and expected to grow at a CAGR of 7.4% due to early screening trends and high-risk population awareness.
• Germany held USD 0.49 Billion in 2025 with a 16.2% share and is projected to grow at a CAGR of 7.1%, supported by insurance coverage for genetic testing.
• India recorded USD 0.37 Billion in 2025, securing a 12.2% share and expected to grow at a CAGR of 7.5% due to rising urban health screening programs and increased diagnosis in metros.

Age 55-75

This group dominates prostate cancer diagnostics due to higher risk, longer life expectancy, and consistent health check-ups. Over 57% of all diagnosed cases fall within this age bracket. There has been a 31% increase in biomarker utilization and a 36% rise in imaging tests such as mpMRI for this age group.

The Age 55-75 segment held the largest share in the prostate cancer diagnostics market, reaching USD 9.25 Billion in 2025, representing 55% of the total market. This segment is projected to grow at a CAGR of 8.1% from 2025 to 2034, driven by aging populations, awareness programs, and government initiatives.

Top 3 Major Dominant Countries in the Age 55-75 Segment

• United States led the Age 55-75 segment with a market size of USD 3.70 Billion in 2025, holding a 40% share and growing at a CAGR of 8.2% due to advanced diagnostics and consistent follow-ups in men aged 55–75.
• United Kingdom held USD 1.05 Billion in 2025 with an 11.3% share and a CAGR of 7.9%, backed by NHS-led cancer awareness campaigns.
• Japan recorded USD 0.89 Billion in 2025, with a 9.6% share and projected CAGR of 8.0%, driven by national aging trends and strong urology networks.

Age Above 75

Diagnostics in the 75+ age group are increasing due to longevity and improved geriatric healthcare access. Around 25% of prostate cancer cases are diagnosed in this group. However, aggressive diagnostic intervention is moderate, with 19% preference for minimally invasive testing and 17% for active surveillance techniques.

The Age Above 75 segment is estimated to reach USD 4.53 Billion in 2025, capturing 27% of the market share. It is expected to grow at a CAGR of 7.4% from 2025 to 2034, supported by aging demographics, non-invasive diagnostics, and geriatric healthcare programs.

Top 3 Major Dominant Countries in the Age Above 75 Segment

• United States led the Age Above 75 segment with a market size of USD 1.85 Billion in 2025, holding a 40.8% share and growing at a CAGR of 7.5% due to advanced care options for elderly patients and insurance inclusion.
• Italy held USD 0.61 Billion in 2025 with a 13.5% share and projected CAGR of 7.3%, attributed to a high elderly male population and government-supported healthcare plans.
• Spain recorded USD 0.48 Billion in 2025, with a 10.5% share and CAGR of 7.2%, driven by structured elderly screening programs and strong hospital coverage.

Prostate Cancer Diagnostics Market Regional Outlook

The global prostate cancer diagnostics market is geographically segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. North America remains the dominant region with the highest technological adoption and strong healthcare infrastructure. Europe follows with significant investments in precision diagnostics and public health programs. Asia-Pacific is experiencing rapid growth due to rising awareness and increasing screening programs, while the Middle East & Africa is gradually emerging with targeted health initiatives. In 2025, North America will hold a 42% market share, Europe 28%, Asia-Pacific 22%, and the Middle East & Africa 8%, totaling 100% of the global market share.

North America

North America leads the prostate cancer diagnostics landscape with high adoption of advanced screening techniques such as genomic tests and mpMRI. Over 54% of male cancer screening tests conducted annually in this region include prostate-specific antigen (PSA) testing. Integration of AI in diagnostic labs has risen by 31%, and clinical trials participation for novel diagnostics has surged by 27% in the last year.

North America held the largest share in the prostate cancer diagnostics market, accounting for USD 7.06 Billion in 2025, representing 42% of the total market. This region is expected to grow at a CAGR of 8.0% from 2025 to 2034, driven by advanced healthcare infrastructure, reimbursement coverage, and widespread awareness.

North America - Major Dominant Countries in the Prostate Cancer Diagnostics Market

• United States led North America with a market size of USD 5.61 Billion in 2025, holding a 79.4% share and expected to grow at a CAGR of 8.1% due to strong diagnostic capabilities and national screening policies.
• Canada held USD 1.03 Billion in 2025 with a 14.6% share and expected to grow at a CAGR of 7.8% due to government-funded health coverage and technological uptake.
• Mexico secured USD 0.42 Billion in 2025, with a 5.9% share and projected CAGR of 7.6%, supported by expanding private healthcare services and awareness campaigns.

Europe

Europe continues to strengthen its position in prostate cancer diagnostics with strong public health systems and rapid adoption of biomarker testing. PSA screening is widespread, used in 61% of diagnostic consultations. Germany, the UK, and France dominate the region, accounting for over 65% of Europe’s total segment share. The rise of AI integration and centralized diagnostic labs has improved diagnosis accuracy by 24%.

Europe is expected to reach USD 4.71 Billion in 2025, capturing 28% of the global prostate cancer diagnostics market. It is forecasted to grow at a CAGR of 7.7% from 2025 to 2034, supported by structured screening programs and strong healthcare access.

Europe - Major Dominant Countries in the Prostate Cancer Diagnostics Market

• Germany led Europe with a market size of USD 1.68 Billion in 2025, holding a 35.6% share and expected to grow at a CAGR of 7.9% due to efficient diagnostic frameworks and genomic test adoption.
• United Kingdom held USD 1.23 Billion in 2025, capturing a 26.1% share and projected to grow at a CAGR of 7.5%, backed by NHS-led screening and AI deployment.
• France recorded USD 0.93 Billion in 2025, holding a 19.7% share and forecasted to grow at a CAGR of 7.6%, due to expanding diagnostic services and awareness drives.

Asia-Pacific

Asia-Pacific is emerging as a high-growth region in prostate cancer diagnostics due to increasing healthcare investments and awareness. Screening rates have improved by 33%, and urban centers report a 39% growth in PSA testing. The use of digital platforms for diagnostics has increased by 26%, especially in China, Japan, and India, driving market momentum in the region.

Asia-Pacific is projected to generate USD 3.70 Billion in 2025, accounting for 22% of the global market. The region is expected to expand at a CAGR of 8.3% from 2025 to 2034, propelled by large population bases, healthcare digitization, and improved access to diagnostic tools.

Asia-Pacific - Major Dominant Countries in the Prostate Cancer Diagnostics Market

• Japan led the Asia-Pacific with a market size of USD 1.37 Billion in 2025, holding a 37.0% share and expected to grow at a CAGR of 8.2% due to aging demographics and early detection systems.
• China held USD 1.05 Billion in 2025 with a 28.4% share and is forecasted to grow at a CAGR of 8.5%, supported by expanding health infrastructure and diagnostic penetration.
• India secured USD 0.72 Billion in 2025, accounting for 19.5% of the segment and projected to grow at a CAGR of 8.7% due to public-private initiatives and urban screening programs.

Middle East & Africa

The Middle East & Africa region is gradually expanding its presence in the prostate cancer diagnostics market through national screening campaigns and growing access to healthcare. Urban areas show a 23% increase in PSA usage, and biomarker-based tests are gaining traction, with 18% more clinics adopting them. Diagnostic awareness has improved by 21% across the GCC nations.

The Middle East & Africa region is expected to reach USD 1.34 Billion in 2025, representing 8% of the global market share. It is projected to grow at a CAGR of 6.9% from 2025 to 2034, fueled by increasing investment in healthcare and early cancer detection programs.

Middle East & Africa - Major Dominant Countries in the Prostate Cancer Diagnostics Market

• Saudi Arabia led the region with a market size of USD 0.52 Billion in 2025, holding a 38.8% share and expected to grow at a CAGR of 7.0% due to advanced hospital facilities and government-led diagnostics programs.
• United Arab Emirates held USD 0.39 Billion in 2025, representing a 29.1% share and projected CAGR of 6.8%, driven by private healthcare expansion and awareness initiatives.
• South Africa secured USD 0.27 Billion in 2025, with a 20.1% share and a CAGR of 6.7%, supported by rising cancer screening campaigns and access to diagnostic labs.

List of Key Prostate Cancer Diagnostics Market Companies Profiled

Investment Analysis and Opportunities in Prostate Cancer Diagnostics Market

Investments in prostate cancer diagnostics are growing substantially, with over 41% of healthcare startups targeting oncology diagnostics in 2024. Among total diagnostic sector funding, 33% was allocated to cancer biomarker R&D. Private equity participation in imaging solutions rose by 28%, driven by AI-enhanced detection technologies. In emerging markets, public-private partnerships contributed to a 22% rise in access-based projects. Investors are prioritizing non-invasive diagnostics, with liquid biopsy funding increasing by 30%. Hospital groups also increased procurement budgets by 26% to acquire precision diagnostic tools. These trends highlight strong opportunities in advanced diagnostics, AI-integrated testing, and personalized screening innovations across global markets.

New Products Development

New product development in prostate cancer diagnostics is accelerating, with 35% of manufacturers expanding their product lines in 2024. AI-powered diagnostic tools saw a 31% rise in launches, particularly in image analysis and PSA automation. Genomic testing kits registered a 27% product release growth, especially in North America and Europe. At-home PSA kits gained market attention, increasing availability by 22% due to demand for remote screening. Liquid biopsy innovations rose by 29%, targeting early-stage detection with non-invasive sampling. Additionally, 18% of new devices launched integrated multi-parameter analytics, offering combined biomarker and imaging reports. These innovations enhance diagnostic accuracy, speed, and accessibility.

Recent Developments

• Abbott launched PSA QuickScan platform: This AI-enabled platform enhances PSA reading accuracy by 24% and reduces test turnaround time by 36%, significantly improving clinical efficiency across diagnostic centers in North America.
• Roche expanded its biomarker portfolio: Roche introduced two new genomic-based biomarker tests that demonstrated a 31% improvement in early-stage prostate cancer detection among male patients aged 55–75.
• Siemens Healthcare introduced SmartMRI Suite: A new imaging software platform that increased prostate lesion localization accuracy by 28%, adopted by over 120 clinical imaging centers globally.
• Genomic Health unveiled ProScore Prostate Panel: This gene expression panel offers an 18% higher accuracy in predicting aggressive cancers, adopted in 15% more oncology hospitals compared to the previous version.
• MDx Health deployed RealTime Dx Tracker: A cloud-based monitoring tool that tracks biomarker fluctuations, increasing follow-up diagnostic efficiency by 26% and reducing unnecessary biopsies by 21%.

Report Coverage

This comprehensive report on the global prostate cancer diagnostics market offers in-depth analysis of market segmentation by type, application, and region. The study covers market size projections, competitive landscape, key regional outlooks, and company strategies. It provides a detailed breakdown of diagnostic types including biomarker tests, imaging, biopsy, and other emerging technologies. Application-wise, segmentation is analyzed across age demographics, with the 55–75 group contributing 55% of the total market share in 2025. The report also includes insights into regional dynamics, showing North America as the leading contributor with 42% market share, followed by Europe at 28%, Asia-Pacific at 22%, and the Middle East & Africa at 8%. Furthermore, it profiles 11 major industry players, with Roche and Abbott leading the market with a combined share exceeding 32%. The study presents recent innovations such as AI-powered platforms and genomic-based test panels. Additionally, it highlights investment trends, where 33% of diagnostic funding is dedicated to cancer biomarkers. Overall, this report serves as a strategic resource for investors, manufacturers, and healthcare stakeholders seeking data-driven insights and opportunities in prostate cancer diagnostics.